Enzyme based antibody Enhancement– A brief history description
Several antibody based cancer therapies counts on activation of the body immune system using so called Antibody Dependent Cell-mediated Cytotoxicity (ADCC). The antibodies bind to antigens on cancer cells and once connected, the antibody attracts immune cells to damage the cancer cells.
For example, the anti-CD20 antibody which is used for treatment of lymphoma and also leukemia, binds to surface particles on cancer cells as well as turns on cytotoxic immune cells to kill the cancer cells. The immune cells are turned on via binding of the Fc-part of the antibody to so called Fc-gamma receptors on the cell surface of the immune cells.
The Fc-gamma receptors are involved in the restorative effector functions of various antibodies and typically needed to obtain enough effect. Nonetheless, due to the abundancy of normal IgG in blood, the Fc-gamma receptors are occupied by IgG and also the healing antibodies needs to contend for binding to the Fc-gamma receptors.
For this reason pre-treatment with imlifidase or EndoS has the possible to potentiate currently readily available antibody based cancer cells treatments. Results from artificial insemination and in vivo testing of the concept has been released in Mol Cancer Ther. 2017 Sep; 16( 9 ):1887 -1897 with the title “Chemical inactivation of endogenous IgG by IdeS improves therapeutic antibody efficiency”.